Neurodegeneration including optic nerve atrophy, spastic ataxia, and progressive cerebral atrophy is a clinical hallmark in patients suffering from pathogenic AFG3L2 variants (Caporali et al., 2020; Jin et al., 2023; Pareek and Pallanck, 2020). Here, AFG3L2 is linked to spastic ataxia.